Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | ESRRG | P62508 | 5/20 | 0.35 |
| ▸ | ESRRB | O95718 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GUSB | P08236 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970358 | 0.82 | ESRRG (0.38) | ESR1ESR2ESRRGESRRBALDH1A1 | |
| SCHEMBL1968656 | 0.80 | ESRRG (0.38) | ESR1ESR2ESRRGESRRBALDH1A1 | |
| SCHEMBL1970164 | 0.79 | POLB (0.41) | ESR1ESR2ESRRGESRRBALDH1A1 | |
| SCHEMBL1969036 | 0.78 | MAOB (0.39) | ESR1ESR2ESRRGESRRBALDH1A1 | |
| SCHEMBL1971759 | 0.76 | POLB (0.40) | ESR1ESR2ALDH1A1CYP3A4CHRM2 | |
| SCHEMBL1969109 | 0.74 | PKM (0.39) | ESR1ESR2ESRRGESRRBALDH1A1 | |
| SCHEMBL1970446 | 0.74 | ESR1 (0.43) | ESR1ESR2ESRRGESRRBALDH1A1 | |
| SCHEMBL13305942 | 0.72 | MEN1 (0.38) | ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL834511 | 0.68 | CHRM2 (0.53) | ESR1ESR2ESRRGALDH1A1CYP3A4 | |
| SCHEMBL3573740 | 0.68 | CNR1 (0.53) | ESR1ESR2ESRRGALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | ESR1 156/4885ESR2 185/4885ESRRG 246/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | ESR1 156/4885ESR2 187/4885ESRRG 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.